Assembly Biosciences (ASMB) Operating Leases (2019 - 2026)

Assembly Biosciences' Operating Leases history runs 8 years deep, the most recent figure standing at $1.9 million for Q1 2026.

• On a quarterly basis, Operating Leases fell 23.69% year-over-year to $1.9 million in Q1 2026; TTM through Mar 2026 was $1.9 million, a 23.69% decrease from a year earlier, with the FY2025 full-year figure at $2.1 million, down 21.65% from the prior year.
• Operating Leases eased to $1.9 million in Q1 2026 per ASMB's latest filing, from $2.1 million in the prior quarter.
• Across five years, Operating Leases topped out at $2.6 million in Q4 2024 and bottomed at $50000.0 in Q3 2023.
• The 5-year median for Operating Leases is $1.1 million (2023), against an average of $1.3 million.
• Across the five-year window, Operating Leases sank 96.96% in 2022 and jumped 1853.1% in 2025, its largest moves.
• Year by year, Operating Leases stood at $101000.0 in 2022, then soared by 1010.89% to $1.1 million in 2023, then soared by 134.22% to $2.6 million in 2024, then dropped by 21.65% to $2.1 million in 2025, then fell by 7.67% to $1.9 million in 2026.
• Per Business Quant, the three latest ASMB Operating Leases figures stand at $1.9 million (Q1 2026), $2.1 million (Q4 2025), and $2.2 million (Q3 2025).